Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GB-0895 in Adults With Mild to Moderate Asthma or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)

NCT07116889 is registered in ClinicalTrials.gov with Generate Biomedicines as lead sponsor.

NCT NCT07116889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07116889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GB-0895 in Adults With Mild to Moderate Asthma or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Generate Biomedicines
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 12, 2023
Completion date
May 31, 2027
Enrollment
156 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, copd (chronic obstructive pulmonary disease)